KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moodys (MCO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Moodys (MCO) over the last 17 years, with Q3 2025 value amounting to $2.2 billion.

  • Moodys' Cash & Equivalents fell 1744.89% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year decrease of 1744.89%. This contributed to the annual value of $2.4 billion for FY2024, which is 1305.16% up from last year.
  • Moodys' Cash & Equivalents amounted to $2.2 billion in Q3 2025, which was down 1744.89% from $2.2 billion recorded in Q2 2025.
  • In the past 5 years, Moodys' Cash & Equivalents ranged from a high of $2.8 billion in Q2 2021 and a low of $1.6 billion during Q2 2022
  • Its 5-year average for Cash & Equivalents is $2.2 billion, with a median of $2.2 billion in 2025.
  • As far as peak fluctuations go, Moodys' Cash & Equivalents crashed by 4243.5% in 2022, and later soared by 4087.82% in 2023.
  • Quarter analysis of 5 years shows Moodys' Cash & Equivalents stood at $1.8 billion in 2021, then fell by 2.32% to $1.8 billion in 2022, then rose by 20.41% to $2.1 billion in 2023, then grew by 13.05% to $2.4 billion in 2024, then decreased by 9.43% to $2.2 billion in 2025.
  • Its Cash & Equivalents stands at $2.2 billion for Q3 2025, versus $2.2 billion for Q2 2025 and $2.1 billion for Q1 2025.